Plasma apelin levels, blood pressure and cardiovascular risk factors in a coastal Chinese population

References

• Charles CJ. Putative role for apelin in pressure/volume homeostasis and cardiovascular disease. Cardiovsc Hematol Agents Med Chem. 2007;5:1–10.
   PubMedGoogle Scholar
• Tatemoto K, Hosoya M, Habata Y, Fujii R, Kakegawa T, Zou MX, et al. Isolation and characterization of a novel endogenous peptide ligand for the human APJ receptor. Biochem Biophys Res Commun. 1998;251:471–6.
   PubMed Web of Science ®Google Scholar
• Lee DK, Cheng R, Nguyen T, Fan T, Kariyawasam AP, Liu Y, et al. Characterization of apelin, the ligand for the APJ receptor. J Neurochem. 2000;74:34–41.
   PubMed Web of Science ®Google Scholar
• Kleinz MJ, Davenport AP. Immunocytochemical localization of the endogenous vasoactive peptide apelin to human vascular and endocardial endothelial cells. Regul Pept. 2004;118:119–25.
   PubMed Web of Science ®Google Scholar
• Hosoya M, Kawamata Y, Fukusumi S, Fujii R, Habata Y, Hinuma S, et al. Molecular and function characteristic of APJ: tissue distribution of mRNA and interaction with the endogenous ligand apelin. J Biol Chem. 2000;275:21061–7.
   PubMed Web of Science ®Google Scholar
• Cheng X, Cheng XS, Pang CC. Venous dilator effect of apelin, an endogenous peptide ligand for the orphan APJ receptor, in conscious rats. Eur J Pharmacol. 2003;470:171–5.
   PubMed Web of Science ®Google Scholar
• Lee DK, Saldivia VR, Nguyen T, Cheng R, George SR, O’Dowd BF. Modification of the terminal residue of apelin-13 antagonizes its hypotensive action. Endocrinology. 2005;146:231–6.
   PubMed Web of Science ®Google Scholar
• Salcedo A, Garijo J, Monge L, Fernández N, Luis García-Villalón A, Sánchez Turrión V, et al. Apelin effects in human splanchnic arteries. Role of nitric and prostanoids. Regul Pept. 2007;144:50–5.
   PubMed Web of Science ®Google Scholar
• Japp AG, Gruden NL, Amer DA, Li VK, Goudie EB, Johnston NR, et al. Vascular effects of apelin in vivo in man. J Am Coll Cardiol. 2008;52:908–13.
   PubMed Web of Science ®Google Scholar
• Tatemoto K, Takayama K, Zou MX, Kumaki I, Zhang W, Kumano K, et al. The novel peptide apelin lowers blood pressure via a nitric oxide-dependent mechanism. Regul Pept. 2001;99:87–92.
   PubMed Web of Science ®Google Scholar
• Ishida J, Hashimoto T, Hashimoto Y, Nishiwaki S, Iguchi T, Harada S, et al. Regulatory roles for APJ, a seven-transmembrane receptor related to angiotensin-type 1 receptor in blood pressure in vivo. J Biol Chem. 2004;279:26274–9.
   PubMed Web of Science ®Google Scholar
• Barnes GD, Alam S, Carter G, Pedersen CM, Lee KM, Hubbard TJ, et al. Sustained cardiovascular actions of APJ agonism during renin-angiotensin system activation and in patients with heart failure. Circ Heart Fail. 2013;6:482–91.
   PubMed Web of Science ®Google Scholar
• American Diabetes Association. Standards of medical care in diabetes—2011. Diabetes Care. 2011;34:S11–61.
   PubMed Web of Science ®Google Scholar
• Jia YX, Lu ZF, Zhang J, Pan CS, Yang JH, Zhao J, et al. Apelin activates L-arginine/nitric oxide synthase/nitric oxide pathway in rat aortas. Peptides. 2007;28:2023–9.
   PubMed Web of Science ®Google Scholar
• Zhong JC, Huang DY, Liu GF, Jin HY, Yang YM, Li YF, et al. Effects of all-trans retinoic acid on orphan receptor APJ signaling in spontaneously hypertensive rats. Cardiovasc Res. 2005;65:743–50.
   PubMed Web of Science ®Google Scholar
• Zhong JC, Huang DY, Yang YM, Li YF, Liu GF, Song XH, et al. Upregulation of angiotension-converting enzyme 2 by all-trans retinoic acid in spontaneously hypertensive rats. Hypertension. 2004;44:907–12.
   PubMed Web of Science ®Google Scholar
• Sonmez A, Celebi G, Erdem G, Tapan S, Genc H, Tasci I, et al. Plasma apelin and ADMA levels in patients with essential hypertension. Clin Exp Hypertens. 2010;32:179–83.
   PubMed Web of Science ®Google Scholar
• Strazynska A, Bryl W, Hoffmann K, Pupek-Musialik D. The estimation of concentration of apelin, insulin, fasting glucose and anthropometric factors in young hypertensive patients. J Hypertens. 2010;28 (e-Supplement A):e187.
   Google Scholar
• Li WW, Niu WQ, Zhang Y, Wu S, Gao PJ, Zhu DL. Family-based analysis of apelin and AGTRL1 gene polymorphisms with hypertension in Han Chinese. J Hypertens. 2009;27:1194–201.
   PubMed Web of Science ®Google Scholar
• Niu W, Wu S, Zhang Y, Li W, Ji K, Gao P, et al. Validation of genetic association in apelin-AGTRL1 system with hypertension in a larger Han Chinese population. J Hypertens. 2010;28:1854–61.
   PubMed Web of Science ®Google Scholar
• Wang W, Lee ET, Fabsitz RR, Devereux R, Best L, Welty TK, et al. A longitudinal study of hypertension risk factors and their relation to cardiovascular disease: the Strong Heart Study. Hypertension. 2006;47:403–9.
   PubMed Web of Science ®Google Scholar
• Sung KC, Suh JY, Kim BS, Kang JH, Kim H, Lee MH, et al. High sensitivity C-reactive protein as an independent risk factor for essential hypertension. Am J Hypertens. 2003;16:429–33.
   PubMed Web of Science ®Google Scholar
• Andrievskaia EM, Ivleva AIa, Minina ES, Lagutina OE. [Predictive value C-reactive protein assessment level in women with arterial hypertension]. Kardiologiia. 2011;51:32–8.
   PubMed Web of Science ®Google Scholar